|Articles|April 10, 2018
Shanghai HEP Pharma Signs Agreement with OmniComm Systems
Advertisement
Shanghai HEP Pharma Co. has signed a new agreement with OmniComm Systems, Inc which will officially name them as TrialMaster's first customer in China. Under this agreement, Shanghai HEP Pharma will use OmniComm's TrialMaster EDC to conduct a hepatitis B study.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Two New Partnerships Aim to Expand Patient Access to Clinical Trials Through Community-Based Research
2
From Study-by-Study to Portfolio Recruitment: Q&A with Gaynor Anders, Trialbee
3
ACT Brief: Portfolio-Level Recruitment Strategy, Structural Change Through Systems Thinking, and Kidney Function Preservation in IgAN
4
ACT Brief: Sponsor Accountability in Outsourcing, Biomarker Strategy in Precision Oncology, and Novel Sciatica Therapy
5